NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
World First: CorWave’s Undulating Membrane Heart Pump Implanted in First Patient<
09 Jul 2025

World First: CorWave’s Undulating Membrane Heart Pump Implanted in First Patient

Early results suggest the pulsatility is preserved which could lead to a reduction of adverse events
VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery<
08 Jul 2025

VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery

Enables initiation of global EquilibriX-S trial later this year
Repronovo announces first participant included in U.S. Phase 2 trial of RPN-001 for male infertility<
01 Jul 2025

Repronovo announces first participant included in U.S. Phase 2 trial of RPN-001 for male infertility

No FDA-approved oral therapies currently exist for this underserved population
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat<
30 Jun 2025

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

“Lorundrostat in Participants with Uncontrolled and Treatment-Resistant Hypertension” is featured in the June 30, 2025 issue.
ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke<
18 Jun 2025

ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke

Clinical Evidence Shows High Reperfusion and First Pass Success Rates with the Device
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)<
18 Jun 2025

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria<
17 Jun 2025

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

Crossover trial met the primary endpoint and demonstrated clinically meaningful reductions
Anaconda Biomed Appoints Dr. Charles Carignan as New Chairman of the Board of Directors<
11 Jun 2025

Anaconda Biomed Appoints Dr. Charles Carignan as New Chairman of the Board of Directors

Dr. Carignan brings extensive clinical, product development, commercialization, and leadership expertise to the role.
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration<
11 Jun 2025

Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration

This proof-of-concept study provides compelling support for the selected dosing regimen of MTx’s investigational BK polyomavirus-neutralizing antibody
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines<
11 Jun 2025

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

Ysios Capital joins SpliceBio's $135 Million Series B Financing.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.